Gianfranco Catalano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gianfranco Catalano has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Nelida Ines Noguera
LIFE Institute for Research and Health Care—Santa Lucia IRCCS, Via del Fosso di Fiorano 64, 00143 Rome, Italy
11 shared publications - Maria Teresa Voso
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
5 shared publications - Paolo de Fabritiis
Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy
5 shared publications - Mariadomenica Divona
Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy
4 shared publications - Pasquale Niscola
Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), Rome, Italy
4 shared publications - Tiziana Ottone
Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy
4 shared publications
Latest Publications
- Open Access
AML Metabolism: A Dynamic Continuum of Functional Dependencies
Metabolic reprogramming is increasingly recognized as a fundamental component of acute myeloid leukemia (AML) biology, but AML cannot be defined by a single metabolic phenotype. Leukemic cells occupy dynamic metabolic states shaped by differentiation, genetic background, the bone marrow microenvironment, and therapeutic pressure. In this Review, we propose that metabolic biomarkers should capture functional dependencies and metabolic plasticity rather than static metabolic states, with functional dependencies defined as the reliance of AML cells on a specific metabolic pathway or process for their survival, proliferation or maintenance, rather than a simple glycolytic-versus-oxidative dichotomy. Normal hematopoietic stem cells (HSCs), leukemic stem cells (LSCs), and bulk AML blasts display distinct metabolic programs. Quiescent HSCs maintain a low-energy state, whereas LSCs rely strongly on mitochondrial oxidative phosphorylation (OXPHOS), amino acid metabolism, mitochondrial quality control, and antioxidant defenses. AML blasts exhibit greater metabolic heterogeneity and can switch between glycolytic and oxidative pathways. Importantly, increased mitochondrial activity does not necessarily indicate an LSC phenotype, as therapy-resistant AML cells may acquire enhanced OXPHOS, fatty acid oxidation (FAO), and mitochondrial fitness as adaptive states. Acute promyelocytic leukemia (APL) provides a model of lineage-specific metabolic rewiring, with PML::RARA suppressing glycolysis while promoting FAO, TCA cycle activity, OXPHOS, and arginine-associated anaplerosis. We propose that metabolic biomarkers should identify functional dependencies and escape routes. Integrating metabolic profiling with multi-omics approaches may enable identification of AML subgroups with distinct vulnerabilities and guide rational combination therapies.
Open AccessAML Metabolism: A Dynamic Continuum of Functional Dependencies
Metabolic reprogramming is increasingly recognized as a fundamental component of acute myeloid leukemia (AML) biology, but AML cannot be defined by a single metabolic phenotype. Leukemic cells occupy dynamic metabolic states shaped by differentiation, genetic background, the bone marrow microenvironment, and therapeutic pressure. In this Review, we propose that metabolic biomarkers should capture functional dependencies and metabolic plasticity rather than static metabolic states, with functional dependencies defined as the reliance of AML cells on a specific metabolic pathway or process for their survival, proliferation or maintenance, rather than a simple glycolytic-versus-oxidative dichotomy. Normal hematopoietic stem cells (HSCs), leukemic stem cells (LSCs), and bulk AML blasts display distinct metabolic programs. Quiescent HSCs maintain a low-energy state, whereas LSCs rely strongly on mitochondrial oxidative phosphorylation (OXPHOS), amino acid metabolism, mitochondrial quality control, and antioxidant defenses. AML blasts exhibit greater metabolic heterogeneity and can switch between glycolytic and oxidative pathways. Importantly, increased mitochondrial activity does not necessarily indicate an LSC phenotype, as therapy-resistant AML cells may acquire enhanced OXPHOS, fatty acid oxidation (FAO), and mitochondrial fitness as adaptive states. Acute promyelocytic leukemia (APL) provides a model of lineage-specific metabolic rewiring, with PML::RARA suppressing glycolysis while promoting FAO, TCA cycle activity, OXPHOS, and arginine-associated anaplerosis. We propose that metabolic biomarkers should identify functional dependencies and escape routes. Integrating metabolic profiling with multi-omics approaches may enable identification of AML subgroups with distinct vulnerabilities and guide rational combination therapies.
- Open Access
- 10 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (11) , 2708-2720
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias
At present there is no metabolic characterization of acute promyelocytic leukemia (APL). Pathognomonic of APL, PML::RARα fusion protein rewires metabolic pathways to feed anabolic tumor cell’s growth. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based therapies render APL the most curable subtype of AML, yet approximately 1% of cases are resistant and 5% relapse. We characterized the metabolic peculiarity and fuel requirement of PML::RARα expressing cells, to identify new targets for tailored therapies in resistant or relapsed APL patients. We analyzed cell metabolism in primary samples from seven APL patients, comparing them with normal CD34+ cells differentiated to promyelocyte and granulocyte, and different PML::RARα expressing cell lines. We show that the PML::RARα oncoprotein inhibits glycolysis, promotes tricarboxylic acid cycle (TCA), and favors long chain fatty acids (LCFA) catabolism. Targeting CD36 function, that promotes the cellular uptake of fatty acids to feed oxidative phosphorylation (OXPHOS), effectively restores sensitivity to ATO in NB4 ATO-resistant clones. Notably, our data demonstrate that glycolytic impairment via AKT inhibition by PML::RARα renders APL cells reliant on OXPHOS. This dependency confers high sensitivity to the VTX-AZA combination, suggesting the therapeutic efficacy of targeted combination treatment in resistant or relapsed APLs.
- 10 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (11) , 2708-2720
Open AccessPML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias
At present there is no metabolic characterization of acute promyelocytic leukemia (APL). Pathognomonic of APL, PML::RARα fusion protein rewires metabolic pathways to feed anabolic tumor cell’s growth. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based therapies render APL the most curable subtype of AML, yet approximately 1% of cases are resistant and 5% relapse. We characterized the metabolic peculiarity and fuel requirement of PML::RARα expressing cells, to identify new targets for tailored therapies in resistant or relapsed APL patients. We analyzed cell metabolism in primary samples from seven APL patients, comparing them with normal CD34+ cells differentiated to promyelocyte and granulocyte, and different PML::RARα expressing cell lines. We show that the PML::RARα oncoprotein inhibits glycolysis, promotes tricarboxylic acid cycle (TCA), and favors long chain fatty acids (LCFA) catabolism. Targeting CD36 function, that promotes the cellular uptake of fatty acids to feed oxidative phosphorylation (OXPHOS), effectively restores sensitivity to ATO in NB4 ATO-resistant clones. Notably, our data demonstrate that glycolytic impairment via AKT inhibition by PML::RARα renders APL cells reliant on OXPHOS. This dependency confers high sensitivity to the VTX-AZA combination, suggesting the therapeutic efficacy of targeted combination treatment in resistant or relapsed APLs.
- Open Access
- 4 July 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 386
Correction: Niscola et al. Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies. Curr. Oncol. 2024, 31, 6632–6658
- 4 July 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (7) , 386
Open AccessCorrection: Niscola et al. Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies. Curr. Oncol. 2024, 31, 6632–6658
- Open Access
Molecular Targets of Oxidative Stress: Focus on Nuclear Factor Erythroid 2–Related Factor 2 Function in Leukemia and Other Cancers
Nuclear factor erythroid 2–related factor 2 (Nrf2) is a transcription factor that plays a central role in regulating cellular responses to oxidative stress. It governs the expression of a broad range of genes involved in antioxidant defense, detoxification, metabolism, and other cytoprotective pathways. In normal cells, the transient activation of Nrf2 serves as a protective mechanism to maintain redox homeostasis. However, the persistent or aberrant activation of Nrf2 in cancer cells has been implicated in tumor progression, metabolic reprogramming, and resistance to chemotherapy and radiotherapy. These dual roles underscore the complexity of Nrf2 signaling and its potential as a therapeutic target. A deeper understanding of Nrf2 regulation in both normal and malignant contexts is essential for the development of effective Nrf2-targeted therapies. This review provides a comprehensive overview of Nrf2 regulation and function, highlighting its unique features in cancer biology, particularly its role in metabolic adaptation and drug resistance. Special attention is given to the current knowledge of Nrf2′s involvement in leukemia and emerging strategies for its therapeutic modulation.
Open AccessMolecular Targets of Oxidative Stress: Focus on Nuclear Factor Erythroid 2–Related Factor 2 Function in Leukemia and Other Cancers
Nuclear factor erythroid 2–related factor 2 (Nrf2) is a transcription factor that plays a central role in regulating cellular responses to oxidative stress. It governs the expression of a broad range of genes involved in antioxidant defense, detoxification, metabolism, and other cytoprotective pathways. In normal cells, the transient activation of Nrf2 serves as a protective mechanism to maintain redox homeostasis. However, the persistent or aberrant activation of Nrf2 in cancer cells has been implicated in tumor progression, metabolic reprogramming, and resistance to chemotherapy and radiotherapy. These dual roles underscore the complexity of Nrf2 signaling and its potential as a therapeutic target. A deeper understanding of Nrf2 regulation in both normal and malignant contexts is essential for the development of effective Nrf2-targeted therapies. This review provides a comprehensive overview of Nrf2 regulation and function, highlighting its unique features in cancer biology, particularly its role in metabolic adaptation and drug resistance. Special attention is given to the current knowledge of Nrf2′s involvement in leukemia and emerging strategies for its therapeutic modulation.
- Open Access
- 24 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6632-6658
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Acute myeloid leukemia (AML) is a heterogeneous blood-related neoplasm that predominantly afflicts older adults with a poor prognosis due to their physical condition and the presence of medical accompanying comorbidities, adverse biological disease features, and suitability for induction intensive chemotherapy and allogenic stem cells transplantation. Recent research into the molecular and biological factors contributing to disease development and progression has led to significant advancements in treatment approaches for older patients with AML. This review article discusses the latest biological and therapeutic developments that are transforming the management of AML in older adults.
- 24 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6632-6658
Open AccessAcute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Acute myeloid leukemia (AML) is a heterogeneous blood-related neoplasm that predominantly afflicts older adults with a poor prognosis due to their physical condition and the presence of medical accompanying comorbidities, adverse biological disease features, and suitability for induction intensive chemotherapy and allogenic stem cells transplantation. Recent research into the molecular and biological factors contributing to disease development and progression has led to significant advancements in treatment approaches for older patients with AML. This review article discusses the latest biological and therapeutic developments that are transforming the management of AML in older adults.
- Open Access
- 24 June 2024
- Published by MDPI AG in Preprints.org
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments
Acute myeloid leukemias (AMLs) are heterogeneous hematologic cancers that occur prevalently in older patients as the result of a complex pathobiology. The clinical outcomes of older patients with AML, often unsuitable for intensive chemotherapy and allogeneic stem cell transplantation, are generally disappointing. However, recent advances in understanding molecular pathogenesis and other biological mechanisms recognized in AML development and progression have changed the treatment approach, especially for this particularly vulnerable category of patients. Indeed, non-intensive biologically tailored approaches, such as combining venetoclax with hypomethylating agents, have changed the therapeutic paradigm in this field. Moreover, other promising compounds and treatment strategies are currently under advanced clinical development. This article delves into the latest biological understanding and therapeutic advances in the clinical management of older AML patients into new conceptual frameworks that progressively transform the clinical practice in this challenging setting.
- 24 June 2024
- Published by MDPI AG in Preprints.org
Open AccessLatest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments
Acute myeloid leukemias (AMLs) are heterogeneous hematologic cancers that occur prevalently in older patients as the result of a complex pathobiology. The clinical outcomes of older patients with AML, often unsuitable for intensive chemotherapy and allogeneic stem cell transplantation, are generally disappointing. However, recent advances in understanding molecular pathogenesis and other biological mechanisms recognized in AML development and progression have changed the treatment approach, especially for this particularly vulnerable category of patients. Indeed, non-intensive biologically tailored approaches, such as combining venetoclax with hypomethylating agents, have changed the therapeutic paradigm in this field. Moreover, other promising compounds and treatment strategies are currently under advanced clinical development. This article delves into the latest biological understanding and therapeutic advances in the clinical management of older AML patients into new conceptual frameworks that progressively transform the clinical practice in this challenging setting.
- Open Access
- 14 February 2023
- Published by Gavin Publishers in Annals of Case Reports
- Vol. 8 (1)
The Value of Tailored Therapy on Survival in High Risk MDS with Del5q: Report of an Unusual Case
Interstitial deletions of chromosome 5q [del (5q)] are the most common cytogenetic abnormality in myelodysplastic syndrome (MDS), accounting for 10-15% of cases [1-3]. The most common breakpoint for (cancel: myelodysplastic syndrome; replacing for: MDS) MDS cases with isolated del (5q) is del (5) (q13q33) [4]. MDS with isolated del (5q) is associated with a relatively favourable prognosis and typical features, which include macrocytic anaemia, thrombocytosis, and the presence of hypolobated megakaryocytes [5]. When this cytogenetic finding occurs in high risk MDS or acute myeloid leukaemia, it is associated with an unfavourable outcome [1]. Treatment approaches differ according to the prognosis with an indication for lenalidomide for low risk MDS with isolated del (5q) [3, 6-8] and a common indication for azacitidine for high risk MDS [3,9], independent of karyotype. The clinical results in higher risk del (5q) MDS by lenalidomide, alone or in combination with azacitidine [10], are still limited [1,11]. In the present case, we report the sequential treatment with azacitidine followed by lenalidomide, upon clearance of bone marrow (BM) blasts that was not planned at the initial treatment stage but as the result of a tailored decision making which took into account the haematological status after six cycles of hypomethylating agent and the patient’s preferences.
- 14 February 2023
- Published by Gavin Publishers in Annals of Case Reports
- Vol. 8 (1)
Open AccessThe Value of Tailored Therapy on Survival in High Risk MDS with Del5q: Report of an Unusual Case
Interstitial deletions of chromosome 5q [del (5q)] are the most common cytogenetic abnormality in myelodysplastic syndrome (MDS), accounting for 10-15% of cases [1-3]. The most common breakpoint for (cancel: myelodysplastic syndrome; replacing for: MDS) MDS cases with isolated del (5q) is del (5) (q13q33) [4]. MDS with isolated del (5q) is associated with a relatively favourable prognosis and typical features, which include macrocytic anaemia, thrombocytosis, and the presence of hypolobated megakaryocytes [5]. When this cytogenetic finding occurs in high risk MDS or acute myeloid leukaemia, it is associated with an unfavourable outcome [1]. Treatment approaches differ according to the prognosis with an indication for lenalidomide for low risk MDS with isolated del (5q) [3, 6-8] and a common indication for azacitidine for high risk MDS [3,9], independent of karyotype. The clinical results in higher risk del (5q) MDS by lenalidomide, alone or in combination with azacitidine [10], are still limited [1,11]. In the present case, we report the sequential treatment with azacitidine followed by lenalidomide, upon clearance of bone marrow (BM) blasts that was not planned at the initial treatment stage but as the result of a tailored decision making which took into account the haematological status after six cycles of hypomethylating agent and the patient’s preferences.
- Open Access
Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment
In the present study, we characterized the metabolic background of different Acute Myeloid Leukemias’ (AMLs) cells and described a heterogeneous and highly flexible energetic metabolism. Using the Seahorse XF Agilent, we compared the metabolism of normal hematopoietic progenitors with that of primary AML blasts and five different AML cell lines. We assessed the efficacy and mechanism of action of the association of high doses of ascorbate, a powerful oxidant, with the metabolic inhibitor buformin, which inhibits mitochondrial complex I and completely shuts down mitochondrial contributions in ATP production. Primary blasts from seventeen AML patients, assayed for annexin V and live/dead exclusion by flow cytometry, showed an increase in the apoptotic effect using the drug combination, as compared with ascorbate alone. We show that ascorbate inhibits glycolysis through interfering with HK1/2 and GLUT1 functions in hematopoietic cells. Ascorbate combined with buformin decreases mitochondrial respiration and ATP production and downregulates glycolysis, enhancing the apoptotic effect of ascorbate in primary blasts from AMLs and sparing normal CD34+ bone marrow progenitors. In conclusion, our data have therapeutic implications especially in fragile patients since both agents have an excellent safety profile, and the data also support the clinical evaluation of ascorbate–buformin in association with different mechanism drugs for the treatment of refractory/relapsing AML patients with no other therapeutic options.
Open AccessAscorbate Plus Buformin in AML: A Metabolic Targeted Treatment
In the present study, we characterized the metabolic background of different Acute Myeloid Leukemias’ (AMLs) cells and described a heterogeneous and highly flexible energetic metabolism. Using the Seahorse XF Agilent, we compared the metabolism of normal hematopoietic progenitors with that of primary AML blasts and five different AML cell lines. We assessed the efficacy and mechanism of action of the association of high doses of ascorbate, a powerful oxidant, with the metabolic inhibitor buformin, which inhibits mitochondrial complex I and completely shuts down mitochondrial contributions in ATP production. Primary blasts from seventeen AML patients, assayed for annexin V and live/dead exclusion by flow cytometry, showed an increase in the apoptotic effect using the drug combination, as compared with ascorbate alone. We show that ascorbate inhibits glycolysis through interfering with HK1/2 and GLUT1 functions in hematopoietic cells. Ascorbate combined with buformin decreases mitochondrial respiration and ATP production and downregulates glycolysis, enhancing the apoptotic effect of ascorbate in primary blasts from AMLs and sparing normal CD34+ bone marrow progenitors. In conclusion, our data have therapeutic implications especially in fragile patients since both agents have an excellent safety profile, and the data also support the clinical evaluation of ascorbate–buformin in association with different mechanism drugs for the treatment of refractory/relapsing AML patients with no other therapeutic options.
- Open Access
PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells
NRF2 (NF-E2 p45-related factor 2) orchestrates cellular adaptive responses to stress. Its quantity and subcellular location is controlled through a complex network and its activity increases during redox perturbation, inflammation, growth factor stimulation, and energy fluxes. Even before all-trans retinoic acid (ATRA) treatment era it was a common experience that acute promyelocytic leukemia (APL) cells are highly sensitive to first line chemotherapy. Since we demonstrated how high doses of ascorbate (ASC) preferentially kill leukemic blast cells from APL patients, we aimed to define the underlying mechanism and found that promyelocytic leukemia/retinoic acid receptor α (PML/RARa) inhibits NRF2 function, impedes its transfer to the nucleus and enhances its degradation in the cytoplasm. Such loss of NRF2 function alters cell metabolism, demarcating APL tissue from both normal promyelocytes and other acute myeloide leukemia (AML) blast cells. Resistance to ATRA/arsenic trioxide (ATO) treatment is rare but grave and the metabolically-oriented treatment with high doses of ASC, which is highly effective on APL cells and harmless on normal hematopoietic stem cells (HSCs), could be of use in preventing clonal evolution and in rescuing APL-resistant patients.
Open AccessPML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells
NRF2 (NF-E2 p45-related factor 2) orchestrates cellular adaptive responses to stress. Its quantity and subcellular location is controlled through a complex network and its activity increases during redox perturbation, inflammation, growth factor stimulation, and energy fluxes. Even before all-trans retinoic acid (ATRA) treatment era it was a common experience that acute promyelocytic leukemia (APL) cells are highly sensitive to first line chemotherapy. Since we demonstrated how high doses of ascorbate (ASC) preferentially kill leukemic blast cells from APL patients, we aimed to define the underlying mechanism and found that promyelocytic leukemia/retinoic acid receptor α (PML/RARa) inhibits NRF2 function, impedes its transfer to the nucleus and enhances its degradation in the cytoplasm. Such loss of NRF2 function alters cell metabolism, demarcating APL tissue from both normal promyelocytes and other acute myeloide leukemia (AML) blast cells. Resistance to ATRA/arsenic trioxide (ATO) treatment is rare but grave and the metabolically-oriented treatment with high doses of ASC, which is highly effective on APL cells and harmless on normal hematopoietic stem cells (HSCs), could be of use in preventing clonal evolution and in rescuing APL-resistant patients.
- Open Access
Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies
This review highlights new findings that have deepened our understanding of the mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia (APL). Promyelocytic leukemia-retinoic acid receptor α (PML-RARa) sets the cellular landscape of acute promyelocytic leukemia (APL) by repressing the transcription of RARa target genes and disrupting PML-NBs. The RAR receptors control the homeostasis of tissue growth, modeling and regeneration, and PML-NBs are involved in self-renewal of normal and cancer stem cells, DNA damage response, senescence and stress response. The additional somatic mutations in APL mainly involve FLT3, WT1, NRAS, KRAS, ARID1B and ARID1A genes. The treatment outcomes in patients with newly diagnosed APL improved dramatically since the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). ATRA activates the transcription of blocked genes and degrades PML-RARα, while ATO degrades PML-RARa by promoting apoptosis and has a pro-oxidant effect. The resistance to ATRA and ATO may derive from the mutations in the RARa ligand binding domain (LBD) and in the PML-B2 domain of PML-RARa, but such mutations cannot explain the majority of resistances experienced in the clinic, globally accounting for 5–10% of cases. Several studies are ongoing to unravel clonal evolution and resistance, suggesting the therapeutic potential of new retinoid molecules and combinatorial treatments of ATRA or ATO with different drugs acting through alternative mechanisms of action, which may lead to synergistic effects on growth control or the induction of apoptosis in APL cells.
Open AccessAcute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies
This review highlights new findings that have deepened our understanding of the mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia (APL). Promyelocytic leukemia-retinoic acid receptor α (PML-RARa) sets the cellular landscape of acute promyelocytic leukemia (APL) by repressing the transcription of RARa target genes and disrupting PML-NBs. The RAR receptors control the homeostasis of tissue growth, modeling and regeneration, and PML-NBs are involved in self-renewal of normal and cancer stem cells, DNA damage response, senescence and stress response. The additional somatic mutations in APL mainly involve FLT3, WT1, NRAS, KRAS, ARID1B and ARID1A genes. The treatment outcomes in patients with newly diagnosed APL improved dramatically since the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). ATRA activates the transcription of blocked genes and degrades PML-RARα, while ATO degrades PML-RARa by promoting apoptosis and has a pro-oxidant effect. The resistance to ATRA and ATO may derive from the mutations in the RARa ligand binding domain (LBD) and in the PML-B2 domain of PML-RARa, but such mutations cannot explain the majority of resistances experienced in the clinic, globally accounting for 5–10% of cases. Several studies are ongoing to unravel clonal evolution and resistance, suggesting the therapeutic potential of new retinoid molecules and combinatorial treatments of ATRA or ATO with different drugs acting through alternative mechanisms of action, which may lead to synergistic effects on growth control or the induction of apoptosis in APL cells.